Pharmaceuticals, Biotechnology and Life Sciences
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have announced an update following the first analysis of the…
Bristol Myers Squibb has selected Leiden, Netherlands to house a new cell therapy manufacturing site in Europe, leveraging the growing…
Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.
Urges Shareholders to Vote “FOR” the Proposed Transaction on the WHITE Proxy Card NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY)…
Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
In addition to today’s news about Yervoy in combination with Opdivo , Bristol-Myers Squibb said today that the European Commission (EC) has…
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
Bristol-Myers Squibb has completed its previously announced acquisition of IFM Therapeutics, the company said on Thursday.
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on three Opdivo-based combination clinical studies in…
Bristol-Myers Squibb announced results from the CheckMate -214 trial on Tuesday, investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma.